Cancer drugs known as ErbB inhibitors have shown great success in treating many patients with lung, breast, colon and other types of cancer. However, ErbB drug resistance means that many other patients do not respond, and ...
Aug 6, 2013
0
1
A team of scientists from A*STAR's Institute of Molecular and Cell Biology (IMCB) have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs. Having the means to identify ...
Aug 6, 2013
0
0
A team of researchers have shown that schizophrenia and a disorder associated with autism and learning difficulties share a common biological pathway. This is one of the first times that researchers have uncovered genetic ...
Aug 4, 2013
0
0
Scientists from the Florida campus of The Scripps Research Institute have described findings that could enable the development of more effective drugs for addiction with fewer side effects.
Aug 2, 2013
0
0
The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests ...
Aug 2, 2013
0
0
A new culprit has been identified that likely plays a big role in the severity of asthma—a small protein chemokine called CCL26. These findings were published in the Journal of Leukocyte Biology and represent the first ...
Aug 1, 2013
0
0
Key molecular pathways that ultimately lead to late-onset Alzheimer's disease, the most common form of the disorder, have been identified by researchers at Columbia University Medical Center (CUMC). The study, which used ...
Jul 24, 2013
0
0
For decades, doctors have understood that microbes in the human gut can influence how certain drugs work in the body—by either activating or inactivating specific compounds—but questions have remained about exactly how ...
Jul 24, 2013
0
0
(Phys.org) —Designer peptides containing chemically stabilized helices emerge as a potent way to activate anti-tumor proteins inside cells.
Jul 17, 2013
0
0
Several more countries have approved Pfizer Inc.'s new rheumatoid arthritis medicine, a twice-a-day pill seen as likely to be a big moneymaker for the company.
Jul 15, 2013
0
0
